dementia Clinical Trials and Research
Also known as: cognitive decline, memory loss, neurocognitive disorder, senility, mild cognitive impairment · ICD-10: F00-F03
Dementia is a broad term for a decline in cognitive abilities severe enough to interfere with daily life. Clinical trial research focuses on understanding its diverse causes, developing new treatments to slow progression, and improving patient care. Find a Trial helps patients search for active studies in this area.
Common questions about dementia clinical trials
Who can participate in dementia clinical trials?
Eligibility criteria vary widely by study, often including factors like age, specific dementia type, and cognitive function scores. Researchers use these criteria to ensure patient safety and gather relevant data, as seen on ClinicalTrials.gov.
What are the different phases of dementia clinical trials?
Clinical trials for dementia typically progress through phases 1, 2, and 3. Phase 1 tests safety, phase 2 evaluates effectiveness and side effects, and phase 3 compares new treatments to existing ones, according to NIH RePORTER data.
Do dementia clinical trials cost money to participate in?
Generally, participants do not pay for study-related treatments or procedures in clinical trials. Some trials may also cover travel or other expenses, but it's important to clarify this with the study team, as detailed on ClinicalTrials.gov.
What are researchers currently investigating in dementia clinical trials?
Current research explores various approaches, including new drugs targeting specific proteins like amyloid or tau, lifestyle interventions, and non-pharmacological therapies. Studies also focus on early detection and prevention strategies, as shown on NIH RePORTER.
What types of interventions are common in dementia clinical trials?
Interventions range from investigational medications aimed at disease modification or symptom management to cognitive training, exercise programs, and dietary changes. Some trials also explore device-based therapies, according to ClinicalTrials.gov.
Are there specific biomarkers used in dementia clinical trials?
Yes, biomarkers like amyloid plaques and tau tangles in the brain, measured by PET scans or CSF analysis, are crucial. Blood-based biomarkers are also being investigated for early detection and monitoring disease progression, as reported on NIH RePORTER.
What might prevent someone from joining a dementia clinical trial?
Common exclusion criteria can include other significant medical conditions, certain medications, or a history of specific neurological disorders. Researchers use these to ensure the study population is appropriate for the intervention being tested, per ClinicalTrials.gov.
Do clinical trials focus on specific types of dementia?
Many trials are designed for specific types, such as Alzheimer's disease, vascular dementia, or Lewy body dementia, due to their distinct underlying causes. However, some studies may encompass broader populations, as seen on ClinicalTrials.gov.
How to find a dementia trial that fits you
- Describe your dementia situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.